Brief: Crescita Announces Positive Results From Late-Stage Studies For Plaque Psoriasis Therapy
11/02/2020 12:39
Feb 11 (Reuters) - Crescita Therapeutics Inc CTX.TO :
* CRESCITA ANNOUNCES POSITIVE TOPLINE RESULTS FROM TWO
PIVOTAL
PHASE 3 CLINICAL STUDIES FOR ITS LEAD PIPELINE PRODUCT IN
PATIENTS WITH PLAQUE PSORIASIS
* CRESCITA THERAPEUTICS INC - PRIMARY ENDPOINT ACHIEVED WITH
HIGH
STATISTICAL SIGNIFICANCE IN TRIAL
* CRESCITA THERAPEUTICS INC - BOTH PHASE 3 STUDIES MET
PRIMARY
ENDPOINT
Source text for Eikon: ID:nCNWllwBpa
Further company coverage: CTX.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Crescita Therapeutics
See all newsBrief: Crescita Therapeutics Obtains Shareholder Approval To Be Acquired By Clinactiv Holdings
Canada's Crescita Q1 revenue rises on manufacturing growth
Canada's Crescita Q4 revenue falls on prior-year one-time reimbursement
Brief: Crescita Reports Q4 And Fiscal 2025 Results
Brief: Crescita Announces Definitive Agreement To Be Acquired By Clinactiv Holdings In An All-Cash Transaction At A Significant Premium